LipocineLPCN
Market Cap: $25.5M
About: Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Employees: 17
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
77% more capital invested
Capital invested by funds: $2.47M [Q1] → $4.38M (+$1.91M) [Q2]
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
6% more funds holding
Funds holding: 18 [Q1] → 19 (+1) [Q2]
1.02% more ownership
Funds ownership: 8.92% [Q1] → 9.94% (+1.02%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for LPCN.